En kombination af immunsuppresiver – såsom antilymfocytiske antistoffer administreret samtidig – øger risikoen for EBV- associerede, lympfoproliferative sygdomme.
A combination of immunosuppressives such as antilymphocytic antibodies given concomitantly increases the risk of EBV-associated lymphoproliferative disorders.